Navigation Links
AbbVie Reports Second-Quarter 2014 Financial Results
Date:7/25/2014

le asset amortization and other specified items.  The gross margin ratio under U.S. generally accepted accounting principles (GAAP) was 77.4 percent.  
  • Adjusted selling, general and administrative (SG&A) expense was 27.1 percent of sales in the second quarter, reflecting continued investment in our growth brands and the expected HCV launch.  On a GAAP basis, SG&A was 29.4 percent of sales.
  •  Adjusted research and development (R&D) was 16.1 percent of sales in the quarter, reflecting funding actions in support of our mid- and late-stage pipeline and the continued pursuit of additional HUMIRA indications.  On a GAAP basis, R&D was 16.9 percent of sales.
  • Net interest expense was $69 million, and the adjusted tax rate was 22.2 percent in the quarter. On a GAAP basis, the second-quarter tax rate was 23.4 percent.
  • Second-quarter diluted earnings per share were $0.68 on a GAAP basis.  Adjusted diluted earnings per share, excluding intangible asset amortization expense and other specified items, were $0.82.  
  • Key Events from the Second Quarter

  • AbbVie announced it reached an agreement with Shire's Board of Directors for a recommended transaction to combine the two companies.  The proposed combination is strategically compelling for both companies and will create a larger and more diversified biopharmaceutical company with multiple leading franchises.  The new company will also have significant financial capacity for future acquisitions, investment and enhanced shareholder distributions and value creation.
  • AbbVie announced the initiation of a Phase 3 clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888), when added to carboplatin and paclitaxel, two chemotherapeutic medicines, in patients with human epidermal growth factor receptor 2-(HER2) negative metastatic or locally-advanced breast cancer, con
    '/>"/>

  • SOURCE AbbVie
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

    Related medicine technology :

    1. AbbVie to Host Second-Quarter Earnings Conference Call
    2. AbbVie to Host Fourth-Quarter and Full-Year 2013 Earnings Conference Call
    3. AbbVie Demonstrates 96 percent SVR(12) in its Phase III Study of Treatment-Experienced Patients with Genotype 1 Hepatitis C
    4. AbbVie Releases First of Six Phase III Results from Investigational All-Oral, Interferon-Free, 12-week Regimen, Showing 96 Percent SVR12 in Genotype 1 Hepatitis C Patients New to Therapy
    5. U.S. Gastroenterologists Have Increased Their TNF-alpha Inhibitor Use Since 2012, Especially for AbbVies Humira, as a Result of Its Recent Approval in Ulcerative Colitis
    6. Financial Results, New Drug Applications, and Stock Price Movements - Research Report on Endo, Bristol-Myers Squibb, Express Scripts, AbbVie, and Incyte
    7. AbbVie Reports Third-Quarter 2013 Financial Results
    8. AbbVie Named a Science Top Employer
    9. AbbVie To Present Investigational Data From Phase II Hepatitis C Program At The Liver Meeting
    10. AbbVie and Galapagos to Co-Develop Cystic Fibrosis Therapies
    11. Strong Sales and Healthcare Reforms Benefit Earnings - Research Report on Gilead, Pfizer, Merck, AbbVie, and LifePoint
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/27/2015)... and HOUSTON, TX , ... the "Company") (TSX-V: EPI) and Bloom Burton & Co. ... from voluntary contractual lock-up (the "Lock-Up") 2,353,130 common shares ... Common Shares originally subject to the Lock-Up. Of the ... be free trading immediately upon release from the Lock-Up ...
    (Date:2/27/2015)... -- Boston Scientific Corporation (NYSE: BSX ) is ... Conference on March 10 in Miami Beach ... vice president and chief financial officer, and Susie ... a 25-minute question and answer session regarding the company ... Following a 5-minute break, a question and answer session ...
    (Date:2/27/2015)... Feb. 27, 2015   Synageva BioPharma Corp. ... company developing therapeutic products for rare diseases, joins ... European Organisation for Rare Diseases™ (EURORDIS™), The Global ... observing Rare Disease Day. On the ... industry, and other participants conduct special events to ...
    Breaking Medicine Technology:ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 3ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 4Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6
    ... Nov. 2, 2010 /PRNewswire-Asia-FirstCall/ -- BMP Sunstone Corporation (Nasdaq: ... today announced that the Company plans to release third ... after the market closes. The Company will ... November 9, 2010 to discuss its results.  Listeners may ...
    ... 2, 2010 Arlington Medical Resources (AMR), ... and diagnostic imaging industries, finds that the leading driver ... States is activity against key drug-resistant pathogens. Such pathogens ... and multidrug-resistant Steptococcus pneumonia. "Nosocomial ...
    Cached Medicine Technology:BMP Sunstone to Report Third Quarter 2010 Financial Results 2Activity Against Key Drug-Resistant Pathogens is the Most Important Attribute Influencing Surveyed Physicians' Antibiotic Selection for Nosocomial Pneumonia in the U.S. 2
    (Date:2/27/2015)... NY (PRWEB) February 27, 2015 In ... to the community by providing free dental care from ... has partnered with Dentistry from the Heart, and ... 11, 2015. The first 50 patients who are in ... they can’t afford, will have access to high­quality service ...
    (Date:2/27/2015)... 2015 The federal court overseeing more ... use of the statin medication can increase a person’s ... new order pertaining discovery in the cases selected for ... comments. The Order, which was issued in the U.S. ... directs the parties to schedule certain witness depositions before ...
    (Date:2/27/2015)... February 27, 2015 According to court ... Hospital on June 25, 2013 and underwent a procedure ... through her mouth. Because the duodenoscope allegedly had ... the antibiotic-resistant “superbug” carbapenem-resistant Enterobacteriaceae (CRE). , ... of Cook County on behalf of Ms. Pirolli alleging ...
    (Date:2/27/2015)... FL (PRWEB) February 27, 2015 ... companies, devices and pharmaceuticals, Benedict Advertising & Marketing ... its newest client. The company’s patented NITROUSEAL® N20 ... pain-free, no-stress method of sedation. , Sedation Systems, ... patient comfort to a new level, though it ...
    (Date:2/27/2015)... The Dawn Greene Hospice, a 10-bed facility located on ... the Upper East Side, was officially dedicated and blessed at ... Timothy Michael Cardinal Dolan. , Thomas J. Fahey, Jr., MD, ... member of the ArchCare Board of Trustees, presided over the ... director of MMW, and Christina McInerney, president and CEO of ...
    Breaking Medicine News(10 mins):Health News:Dr. Umanoff Unites with Dentistry from the Heart to Provide Community with Charitable Dental Care 2Health News:Dr. Umanoff Unites with Dentistry from the Heart to Provide Community with Charitable Dental Care 3Health News:Federal Lipitor Litigation Issues New Order Pertaining to Discovery in Bellwether Cases, Bernstein Liebhard LLP Comments 2Health News:Federal Lipitor Litigation Issues New Order Pertaining to Discovery in Bellwether Cases, Bernstein Liebhard LLP Comments 3Health News:Lawsuit Alleges Blame on Scope Manufacturer for "Superbug" Outbreak 2Health News:Benedict Advertising & Marketing Signs Sedation Systems 2Health News:The Dawn Greene Hospice Is Officially Dedicated 2Health News:The Dawn Greene Hospice Is Officially Dedicated 3
    ... Biology MeetingNEW ORLEANS, April 20 Research presented today ... lower cholesterol by 10 percent in one month. The ... Research, found that eating two 1 1/2 cup servings ... diet low in fat, lowered LDL or "bad" cholesterol ...
    ... longer, study suggests, , , MONDAY, April 20 (HealthDay News) -- Want ... how to manage your stress. , A new study found that ... lived to 100, and longevity is thought to run in families. ... traits that set the children of centenarians apart from other people ...
    ... Who better to provide healthy eating tips than ... Cardiovascular and Wellness Nutrition (SCAN) Dietetic Practice Group of ... the Great Tomato Tip-Off Contest!, a partnership effort between ... encouraged dietitians to send in their best tips for ...
    ... Scientists Discover Eating Cherries May Elevate Antioxidant Activity in ... and a half servings of tart cherries could significantly ... University of Michigan research reported at the ... study, healthy adults who ate a cup and a ...
    ... April 20 /PRNewswire-FirstCall/ - Response Biomedical Corporation (TSX: ... for the three-month period ended March 31, 2009. ... million compared to $1.173 million for the same ... for any quarter in the Company,s history and, ...
    ... Tenn., April 20 HCA Healthcare announces the following Webcast: What: ... 27, 2009 @ 10:00 EST , Where: ... the Internet -- Simply log on to the web , ... Contact: Mark Kimbrough, Investor Relations at HCA Healthcare, , ...
    Cached Medicine News:Health News:Cheerios(R) Can Help Reduce Cholesterol 10 Percent in One Month 2Health News:Cheerios(R) Can Help Reduce Cholesterol 10 Percent in One Month 3Health News:Outgoing Nature Could Get You to 100 2Health News:Outgoing Nature Could Get You to 100 3Health News:The Tomato Products Wellness Council and SCAN Announce Winners for the Great Tomato Tip-Off Contest! 2Health News:The Tomato Products Wellness Council and SCAN Announce Winners for the Great Tomato Tip-Off Contest! 3Health News:New Human Study Reinforces Antioxidant Benefits of Tart Cherries 2Health News:New Human Study Reinforces Antioxidant Benefits of Tart Cherries 3Health News:Response Biomedical Corporation Delivers Record Preliminary Revenues in First Quarter 2Health News:Response Biomedical Corporation Delivers Record Preliminary Revenues in First Quarter 3Health News:Response Biomedical Corporation Delivers Record Preliminary Revenues in First Quarter 4
    1.7/2.2 mm Delta System resorbable implant technology merges science and simplicity for a superior craniomaxillofacial surgery product. The system consists of resorbable bone plates and screws fabric...
    ... A-scan Sonomed-315 is intended for visualization of ... of midline shifts in the brain, evaluation ... easy to use, the Sonomed-315 offers quick ... mode allows to identify the anatomic structures ...
    ... a scaleable device that works ... platelet plasma or buffy coat. ... coat must be prepared independently ... Starting volume and concentration factor ...
    The Ultrafoam Collagen Sponge is indicated in all surgical procedures as an adjunct to hemostasis when control by ligature or conventional procedures are ineffective or impractical....
    Medicine Products: